Alimatravir (MK-8527) is a nucleoside analogue functioning as a potent and selective inhibitor of the hepatitis B virus polymerase, which works by blocking viral DNA replication. Currently under investigation… Read more
Alimatravir (MK-8527) is a nucleoside analogue functioning as a potent and selective inhibitor of the hepatitis B virus polymerase, which works by blocking viral DNA replication. Currently under investigation for the treatment of chronic hepatitis B infection, particularly in patients who have failed or are intolerant to existing therapeutic regimens, this compound serves as the primary reference standard for analytical development. Laboratories utilize the associated metabolites, impurities, and stable isotope labelled compounds, such as deuterated analogues and 13C/15N labelled variants, to ensure precise results during rigorous analytical testing. These reference materials are critical for accurate impurity profiling, method validation, and quantitative assessment in pharmacokinetic studies, providing the necessary precision for characterizing the drug throughout the development lifecycle and supporting quality control processes in pharmaceutical research and manufacturing environments.